Should You Buy Kenvue Stock After Its 30% Plunge?
Johnson & Johnson (NYSE: JNJ) spun off its consumer health unit as a separate entity in 2023. The new business, Kenvue (NYSE: KVUE), inherited a broad lineup of popular products, including Band-Aid adhesive bandages, Listerine mouthwash, Tylenol pain reliever, and Zyrtec allergy medicine. With an arsenal of household names in its lineup and a solid dividend, Kenvue seemed to be the kind of stock many income investors would love. However, this healthcare stock has delivered a decidedly disappointing performance since the spinoff two years ago. And it recently experienced another major sell-off. Should you buy Kenvue after its 30%+ plunge this year?Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Quelle: MotleyFool
Nachrichten zu Kenvue
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Kenvue
Keine Analysen gefunden.